Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
- Conditions
- Interventions
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25086
- Registration Number
- NCT00335452
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia
🇪🇸Sanofi-Aventis Admnistrative Office, Madrid, Spain
Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study
- Conditions
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT00330772
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 216
- Registration Number
- NCT00296803
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation
- Conditions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 250
- Registration Number
- NCT00224809
- Locations
- 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Ullevaal University Hospital
- Target Recruit Count
- 1001
- Registration Number
- NCT00222261
- Locations
- 🇳🇴
Ullevaal University Hospital, Oslo, Norway
The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-10-06
- Lead Sponsor
- Arteriogenesis Competence Network
- Target Recruit Count
- 250
- Registration Number
- NCT00189618
- Locations
- 🇨🇭
University Hospital Basel Dpt. Angiology, Basel, Switzerland
🇨🇭Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭Kantonsspital Bruderholz, Bruderholz, Switzerland
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1460
- Registration Number
- NCT00174759
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-08-09
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 80
- Registration Number
- NCT00163267
- Locations
- 🇩🇪
University Hospital of Tuebingen, Tuebingen, Germany
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20332
- Registration Number
- NCT00153062
- Locations
- 🇺🇸
9.159.1197 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
🇺🇸9.159.1024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸9.159.1005 Boehringer Ingelheim Investigational Site, Fort Smith, Arkansas, United States
Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 85
- Registration Number
- NCT00152724
- Locations
- 🇫🇷
Laboratoire de Physiologie et Explorations Vasculaires - CHU Angers, Angers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.